ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 41 filers reported holding ADC THERAPEUTICS SA in Q3 2023. The put-call ratio across all filers is 2.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $83,152 | -58.8% | 92,700 | -1.2% | 0.08% | -61.6% |
| Q2 2023 | $201,754 | +10.3% | 93,839 | 0.0% | 0.22% | +2.3% |
| Q1 2023 | $182,986 | -49.2% | 93,839 | 0.0% | 0.21% | -45.8% |
| Q4 2022 | $360,342 | -20.3% | 93,839 | 0.0% | 0.40% | -14.7% |
| Q3 2022 | $452,000 | -39.5% | 93,839 | -0.2% | 0.46% | -29.7% |
| Q2 2022 | $747,000 | -47.4% | 93,989 | -2.7% | 0.66% | -38.2% |
| Q1 2022 | $1,419,000 | -27.3% | 96,572 | -0.0% | 1.07% | -24.7% |
| Q4 2021 | $1,951,000 | -26.3% | 96,582 | -0.9% | 1.42% | -33.9% |
| Q3 2021 | $2,646,000 | +18.6% | 97,411 | +6.3% | 2.14% | +18.5% |
| Q2 2021 | $2,231,000 | -0.8% | 91,641 | -0.5% | 1.81% | -29.4% |
| Q1 2021 | $2,249,000 | -23.9% | 92,116 | -0.2% | 2.56% | -25.6% |
| Q4 2020 | $2,954,000 | – | 92,287 | – | 3.44% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vantage Consulting Group Inc | 1,186,215 | $5,718,000 | 3.34% |
| Blue Owl Capital Holdings LP | 733,568 | $3,536,000 | 1.53% |
| Redmile Group, LLC | 7,512,029 | $36,208,000 | 1.40% |
| GCM Grosvenor Holdings, LLC | 735,471 | $3,545,000 | 0.84% |
| Prosight Management, LP | 247,630 | $1,194,000 | 0.64% |
| Indie Asset Partners, LLC | 93,839 | $452,000 | 0.46% |
| MPM BioImpact LLC | 334,384 | $1,612,000 | 0.38% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,390,297 | $11,521,000 | 0.23% |
| Eventide Asset Management | 1,879,959 | $9,061,000 | 0.18% |
| APOGEM CAPITAL LLC | 17,405 | $84,000 | 0.08% |